30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus metho
Paris, France, Friday 13 June 2008: Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA), who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy, according to a new study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. Tocilizumab, an anti-interleukin (IL)-6 receptor monoclonal antibody, was demonstrated to be effective irrespective of the number of, or the most recently-failed anti-TNF treatments. After 24 weeks of treatment, 30.1% (p<0.0001) of patients receiving 8mg/kg tocilizumab plus methotrexate, who had active RA despite prior anti-TNF therapy, achieved DAS28 (a measure of disease remission) compared with only 1.6% in the placebo arm. 50% (p<0.0001) of patients on the same regime achieved the study's primary endpoint of ACR20 (a 20% improvement in symptoms) compared to 10% of patients in the placebo arm. Patients receiving 4mg/kg tocilizumab plus methotrexate experienced similar, though slightly lower results with 7.6% (p=0.0533) achieving DAS28 and 30.4% (p<0.0001) achieving ACR20.
Professor Paul Emery of Leeds Teaching Hospital Trust / Leeds University, UK, lead investigator in the trial, said: "Although anti-TNF therapies for RA are well-established, a substantial number of patients are inadequately controlled by these treatments, or become refractory to them. The results of this trial suggest that tocilizumab offers a much needed and effective option for such patients."
The RADIATE study was a randomised, double-blind study of 499 patients with moderate to severe RA. 12-18% of patients had 3 or more prior anti-TNF failures. A low proportion of the patients in the 8mg/kg tocilizumab group experienced serious adverse effects (6%) or serious infections (5%) during the trial. There was no difference in safety or tolerability based on prior anti-TNF treatment.
- Smoking cigarettes is a predictor of RA and may negatively impact on efficacy of anti-TNFsThu, 17 Jun 2010, 9:45:20 EDT
- IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active ASFri, 12 Jun 2009, 10:36:35 EDT
- New drug shows promising results for psoriatic arthritisTue, 7 Apr 2009, 13:29:37 EDT
- Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patientsThu, 29 Oct 2009, 1:23:53 EDT
- Phase 3 data show efficacy of golimumab in RA patients previously treated with anti-TNF agentsFri, 13 Jun 2008, 11:42:55 EDT
Articles on the same topic
- Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapiesThu, 12 Jun 2008, 10:36:26 EDT
- 30 Percent RA Patients Refractory To Anti-TNFs Achieve Disease Remission With Tocilizumab Plus Methofrom Science DailyFri, 13 Jun 2008, 14:21:25 EDT
- Adalimumab Therapy Effective In AS, RA And PsA Patients Refractory To Other Anti-TNF Therapiesfrom Science DailyThu, 12 Jun 2008, 10:35:29 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Allosaurus fed more like a falcon than a crocodile, new study finds
- Invasive crazy ants are displacing fire ants in areas throughout southeastern US
- Beautiful 'flowers' self-assemble in a beaker
- Scientific insurgents say 'Journal Impact Factors' distort science
- GPS solution provides 3-minute tsunami alerts